Scopus Biopharma IncOver The Counter Market:SCPS
- LAST PRICE0.0003
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0003 / 0.0003
- Day Range
- 52 Week Range
- Volume450
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | SCPS |
|---|---|---|
| 10:04 ET | 450 | 0.0003 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Scopus Biopharma Inc | 12.6K | 0.0x | --- |
VIA Pharmaceuticals Inc | 20.0 | 0.0x | --- |
Psycheceutical Bioscience Inc | 27.6K | 0.0x | --- |
Evelo Biosciences Inc | 28.4K | 0.0x | --- |
Tengion Inc | 40.0 | 0.0x | --- |
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
Company Information
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Contact Information
- Headquarters
- 420 Lexington Ave Rm 300NEW YORK, NY, United States 10170-0399
- Phone
- 212-479-2513
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Principal Executive Officer
- Joshua Lamstein
- Vice Chairman of the Board, Treasurer, Secretary
- Robert Gibson
- President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
- Alan Horsager
- Executive Chairman of Scopus BioPharma Israel Ltd
- Aharon Schwartz
- Director
- Ira Greenspan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.6K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 42.1M |
Scopus Biopharma Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.32 |
Book Value | $-0.31 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
